Ocugen Inc

+0.09 (+6.12%)
4:42:48 PM EDT: $1.55 -0.01 (-0.64%)
Earnings Announcements

Ocugen Reports Third Quarter Results

Published: 11/08/2022 13:42 GMT
Ocugen Inc (OCGN) - Ocugen Provides Business Update & Third Quarter 2022 Financial Results.
Initiated Dosing in Third and Final Cohort of U.S. Phase 1/2 Ocu400 Gene Therapy Clinical Trial.
Expanded Product Pipeline With Ocu500-ocugen's Mucosal Covid-19 Vaccine and Ocu410st for Stargardt Disease.completed Enrollment of U.S. Phase 2/3 Covaxin(™) (bbv152) Clinical Trial.
Believes That Its Current Cash and Cash Equivalents Balance Will Enable It to Fund Its Operations Into Q4 2023.
Cash, Cash Equivalents, and Restricted Cash Totaled $101.6 Million As of September 30, 2022, Compared to $95.1 Million As of December 31, 2021.
Reported a $0.10 Net Loss per Share for Three Months Ended September 30, 2022.
Q3 Earnings per Share View $-0.10 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.17 Million
Adjusted EPS is expected to be -$0.10

Next Quarter Revenue Guidance is expected to be $0.8 Million
Next Quarter EPS Guidance is expected to be -$0.11

More details on our Analysts Page.